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APPENDIX
For supplemental references, a ﬁgure, and a table, please see the online
version of this article.Letters to the EditorApplication of the
Gompertz Method for
Evaluating Survival Gains
in Patients Receiving Cardiac
Resynchronization TherapyIn the paper by Finegold et al. (1), the methods used for the
survival analysis have been described with insufﬁcient detail. It
appears, however, that lifespan gains were calculated through
a separate analysis of each individual trial, were then “weighted
according to study size,” and ﬁnally were “averaged across all trials.”
This step of the survival analysis, which is described by Finegold
et al. (1) in their Results section and not in the Methods, needs to
be clariﬁed in at least 2 aspects. First, the weighting process is
essential to any meta-analysis, because in this way, between-trial
variations are explored and conﬁdence intervals for differences are
estimated. So, one question is why the results were presented
exclusively on the basis of the pooled (or “average”) survival gain,
without any information on the gains calculated for each individual
trial and without any measure of statistical variability. Second, in
the calculation of the trial-speciﬁc lifespan gains, the authors state
that they “used the Gompertz method for this.” However, ﬁtting a
Kaplan-Meier curve to the Gompertz equation is a complex task
from a mathematical and statistical viewpoint (2,3), and it is un-
fortunate that no details were provided on this point.
If these inconsistencies are clariﬁed, this paper can be viewed
as an important contribution in this ﬁeld, mainly for reasons
of cost-effectiveness. Given that the gain of 1 month can be
valued at approximately V5,000 according to common bench-
marks (4–7), this study shows that the clinical beneﬁt of
this procedure is not, as suggested by short-term data, onlyapproximately 1 month (equivalent to V5,000, which would not
even cover the device cost) but could be as high as 6.5 months
(equivalent to more than V30,000, which is much more than the
cost of the device).*Andrea Messori, PharmD
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Res Artic 2003;5:53–67.ReplyApplication of the
Gompertz Method for
Evaluating Survival Gains
in Patients Receiving Cardiac
Resynchronization TherapyWe thank Dr. Messori and colleagues for asking for clariﬁcation on
the Methods used in our recent paper.
We should clarify that our Figure 2 used an average weighted
solely by the sample size of the 5 trials, because this seemed
appropriate weighting for combining rates across trials. The reason
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2880for this graph was to take the same approach used previously by our
group (1) to address the frequently raised question of whether
lifespan gain really does expand progressively with time, even
though many commentators simply state that “one has to implant x
devices to obtain a beneﬁt” without specifying a time window.
Figure 2 shows that no single value is correct for all time windows.
Nothing from Figure 2 is used elsewhere in our paper.
For the lifespan gain calculations in the main paper, we used
hazard ratios published by the trialists themselves, because these
came from the entire trial period, which maximized the information
extracted from the data. All 5 trials provided a hazard ratio, but not
all provided the 95% conﬁdence interval. We could not, therefore,
calculate the ideal inverse-variance–weighted average using the
reciprocal of the conﬁdence interval width and instead used an
unweighted average of the 5 hazard ratios. Lifespan gains were
calculated using a life table with annual deaths calculated from
2 competing hazards. One hazard was amenable to reduction by
cardiac resynchronization therapy device implantation; the other
was not and instead increased annually by a scale factor of 1.1.
The second inquiry was how the Gompertz method was used to
calculate lifespan gain in the post-trial period. We did not attempt
to ﬁt Kaplan-Meier survival curves to the Gompertz equation
because, as Dr. Messori and colleagues rightly point out, this is
mathematically and statistically complex. It would additionally be
unwise to attempt to extract from the trial data the Gompertz
coefﬁcient, which quantiﬁes rising mortality hazard with aging
(equivalent to longer after randomization). First, trials typically do
not report survival for sufﬁciently long periods for curves to show
appreciable convexity (mortality acceleration), that is, the Gom-
pertz coefﬁcient has not yet manifested. Second, because of stag-
gered enrollment, at later times from randomization there are fewer
patients being followed, so random noise dominates the Kaplan-
Meier curves, which further imperils any attempt to extract the
Gompertz coefﬁcient. We therefore set the Gompertz exponent eb
at b¼0.095 per year to scale up the hazard of non–cardiac
resynchronization therapy–preventable mortality by a factor of 1.1
every year, based on the U.S. national census data of 2003.
We thank Dr. Messori and colleagues for helping ensure our
methods are clear and, as always, welcome any further questions via
the Journal or directly.*Judith A. Finegold, MBBS
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Consider How to Balance
Cardiorenometabolic Beneﬁts
and Risks of Statins?Two recent papers demonstrated that atorvastatin 80 mg versus
10 mg reduced periodontal (1) and atherosclerotic plaque (2)
inﬂammation. These studies may explain the results of a study
that showed that atorvastatin 80 mg versus 10 mg provided sig-
niﬁcant cardiovascular beneﬁt in patients with stable coronary heart
disease (3). However, we should keep in mind that these beneﬁts
occurred with a greater incidence of elevated aminotransferase
levels (1.2% vs. 0.2%, p < 0.001) and greater rates of discontinu-
ation because of treatment-related adverse events (7.2% vs. 5.3%,
p < 0.001) and deaths of noncardiovascular causes (3.2% vs. 2.5%,
p ¼ 0.07) (3).
The adverse effects of statins, such as myopathy and liver
toxicity, are dose dependent; however, whether the unwanted effect
of statins on acute renal failure is dose dependent has not been
investigated, much as the unwanted effect of statins to induce type
2 diabetes mellitus has been neglected over the decade. We ﬁrst
reported that high-dose atorvastatin therapy had greater adverse
effects on glucose homeostasis than low-dose atorvastatin therapy
in hypercholesterolemic patients (4). A recent paper delineated an
association between acute kidney injury and use of high-potency
statins versus low-potency statins (5). In patients without chronic
kidney disease, current users of high-potency statins were 34%
more likely to be hospitalized with acute kidney injury within
120 days after starting treatment. High-potency statin use in
chronic kidney disease did not result in as large an increase in
admission rate. The increased risk of admission remains elevated
for at least 2 years.
Nonetheless, statins are very important to prevent cardiovascular
events in patients with a high or even low risk of vascular disease.
However, we should keep in mind that the long-term adverse
effects of new-onset diabetes mellitus or acute kidney injury may
generate a relative increase in deaths. Although some studies have
demonstrated that high-potency statins are associated with an
increased rate of diagnosis of acute kidney injury in hospital ad-
missions and new-onset diabetes mellitus compared with low-
potency statins, the long-term outcome of these unwanted effects
versus cardiovascular outcome is questionable and should be
investigated.*Kwang Kon Koh, MD, PhD
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